curve-fitting function of the sigma plot software (SYSTAT)
SYSTAT is a verified supplier 
90
Structured Review
SYSTAT
curve-fitting function of the sigma plot software
Curve Fitting Function Of The Sigma Plot Software, supplied by SYSTAT, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sigma+plot+curve-fitting+software/sigma+plot+11+0/pmc07346309-63-23-25
Average 90 stars, based on 1 article reviews
Curve Fitting Function Of The Sigma Plot Software, supplied by SYSTAT, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sigma+plot+curve-fitting+software/sigma+plot+11+0/pmc07346309-63-23-25
Average 90 stars, based on 1 article reviews
curve-fitting function of the sigma plot software - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Inhibition:Article Title: Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human. Article Snippet: ISSN 0049-8254 print/ISSN 1366-5928 online © 2009 Informa UK Ltd DOI: 10.1080/00498250903121796 Abstract 1.. 5-{2-[4-(3,4-Difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid (1) is a novel, potent, and selective agonist of the peroxisome proliferator-activated receptor alpha (PPAR-α).. In preclinical species, compound 1 demonstrated generally favourable pharmacokinetic properties. Article Title: Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility. Article Snippet: Elaborate studies of cholesteryl ester transfer protein (CETP) polymorphisms and genetic deficiency in humans suggest direct links between CETP, high-density lipoprotein cholesterol (HDL-c) levels and coronary heart diseases.. The hypothesis that CETP inhibition by small molecule inhibitors raises HDL-c has been validated clinically with structurallydiverse CETP inhibitors such as torcetrapib, anacetrapib, dalcetrapib and evacetrapib.. Despite promising phase 2 results with respect to HDL-c elevation, torcetrapib was discontinued in phase 3 trials due to increased mortality rates in the cardiovascular outcomes study. Article Title: Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Article Snippet: (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-1-hydroxymethyl-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol (PF-04971729), a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2, is currently in phase 2 trials for the treatment of diabetes mellitus.. This article describes the preclinical species and in vitro human disposition characteristics of PF-04971729 that were used in experiments performed to support the first-in-human study.. Plasma clearance was low in rats (4.04 ml min 1 kg ) and dogs (1.64 ml min 1 kg ), resulting in half-lives of 4.10 and 7.63 h, respectively. Software:Article Title: Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human. Article Snippet: ISSN 0049-8254 print/ISSN 1366-5928 online © 2009 Informa UK Ltd DOI: 10.1080/00498250903121796 Abstract 1.. 5-{2-[4-(3,4-Difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid (1) is a novel, potent, and selective agonist of the peroxisome proliferator-activated receptor alpha (PPAR-α).. In preclinical species, compound 1 demonstrated generally favourable pharmacokinetic properties. Article Title: Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility. Article Snippet: Elaborate studies of cholesteryl ester transfer protein (CETP) polymorphisms and genetic deficiency in humans suggest direct links between CETP, high-density lipoprotein cholesterol (HDL-c) levels and coronary heart diseases.. The hypothesis that CETP inhibition by small molecule inhibitors raises HDL-c has been validated clinically with structurallydiverse CETP inhibitors such as torcetrapib, anacetrapib, dalcetrapib and evacetrapib.. Despite promising phase 2 results with respect to HDL-c elevation, torcetrapib was discontinued in phase 3 trials due to increased mortality rates in the cardiovascular outcomes study. Article Title: Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Article Snippet: (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-1-hydroxymethyl-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol (PF-04971729), a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2, is currently in phase 2 trials for the treatment of diabetes mellitus.. This article describes the preclinical species and in vitro human disposition characteristics of PF-04971729 that were used in experiments performed to support the first-in-human study.. Plasma clearance was low in rats (4.04 ml min 1 kg ) and dogs (1.64 ml min 1 kg ), resulting in half-lives of 4.10 and 7.63 h, respectively. |